Lactococcus lactis as an Effective Mucosal Vaccination Carrier: a Systematic Literature Review.

IF 2.5 4区 生物学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Suryanata Kesuma, Tri Yudani Mardining Raras, Sri Winarsih, Takeshi Shimosato, Valentina Yurina
{"title":"<i>Lactococcus lactis</i> as an Effective Mucosal Vaccination Carrier: a Systematic Literature Review.","authors":"Suryanata Kesuma, Tri Yudani Mardining Raras, Sri Winarsih, Takeshi Shimosato, Valentina Yurina","doi":"10.4014/jmb.2411.11036","DOIUrl":null,"url":null,"abstract":"<p><p><i>Lactococcus lactis</i> has potential as a mucosal vaccine delivery system. <i>L. lactis</i> can express antigens from bacteria or viruses, which are tightly controlled using nisin. Although <i>L. lactis</i>-based vaccine shows great promise, no product is ready for human use. Several studies have been conducted to develop <i>L. lactis</i>-based vaccine, and the efficacy of these vaccines has been evaluated in many scientific articles. This paper aims to review key aspects of current knowledge on the promising characteristics of <i>L. lactis</i> and to suggest its implications for vaccine design. Articles were obtained online using inclusion and exclusion criteria through Harzing's Publish or Perish. The article assessment used the Joanna Briggs Institute critical appraisal checklist for quasi-experimental studies. The efficacy evaluation of 24 articles showed that <i>L. lactis</i>-based vaccine can induce IgA and IgG as humoral immune responses; T CD4, T CD8, and B cells as cellular immune responses; and various proinflammatory cytokines such as IFN-γ, TNF-α, IL-2, IL-4, IL-8, IL-10, IL-12, IL-17. <i>L. lactis</i> is suitable as a vector carrier for oral or nasal mucosal vaccines targeting bacterial and viral infections. The development of <i>L. lactis</i> as a vaccine delivery system is promising.</p>","PeriodicalId":16481,"journal":{"name":"Journal of microbiology and biotechnology","volume":"35 ","pages":"e2411036"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925755/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of microbiology and biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.4014/jmb.2411.11036","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Lactococcus lactis has potential as a mucosal vaccine delivery system. L. lactis can express antigens from bacteria or viruses, which are tightly controlled using nisin. Although L. lactis-based vaccine shows great promise, no product is ready for human use. Several studies have been conducted to develop L. lactis-based vaccine, and the efficacy of these vaccines has been evaluated in many scientific articles. This paper aims to review key aspects of current knowledge on the promising characteristics of L. lactis and to suggest its implications for vaccine design. Articles were obtained online using inclusion and exclusion criteria through Harzing's Publish or Perish. The article assessment used the Joanna Briggs Institute critical appraisal checklist for quasi-experimental studies. The efficacy evaluation of 24 articles showed that L. lactis-based vaccine can induce IgA and IgG as humoral immune responses; T CD4, T CD8, and B cells as cellular immune responses; and various proinflammatory cytokines such as IFN-γ, TNF-α, IL-2, IL-4, IL-8, IL-10, IL-12, IL-17. L. lactis is suitable as a vector carrier for oral or nasal mucosal vaccines targeting bacterial and viral infections. The development of L. lactis as a vaccine delivery system is promising.

乳球菌作为一种有效的粘膜疫苗载体:系统的文献综述。
乳酸乳球菌具有作为粘膜疫苗递送系统的潜力。乳杆菌可以表达来自细菌或病毒的抗原,这些抗原是用nisin严格控制的。尽管基于乳杆菌的疫苗显示出巨大的希望,但没有产品可供人类使用。为了开发乳酸菌疫苗,已经进行了几项研究,并且在许多科学文章中对这些疫苗的功效进行了评估。本文旨在回顾目前关于乳酸乳杆菌有希望的特征的知识的关键方面,并提出其对疫苗设计的影响。文章是通过Harzing的出版或灭亡的纳入和排除标准在网上获得的。文章评估使用了准实验研究的乔安娜布里格斯研究所批判性评估清单。24篇文献的疗效评价表明,乳杆菌疫苗可诱导IgA和IgG产生体液免疫反应;T CD4、T CD8和B细胞作为细胞免疫应答;以及各种促炎细胞因子,如IFN-γ、TNF-α、IL-2、IL-4、IL-8、IL-10、IL-12、IL-17。乳酸菌适合作为针对细菌和病毒感染的口腔或鼻黏膜疫苗的载体。乳酸菌作为疫苗递送系统的发展是有希望的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of microbiology and biotechnology
Journal of microbiology and biotechnology BIOTECHNOLOGY & APPLIED MICROBIOLOGY-MICROBIOLOGY
CiteScore
5.50
自引率
3.60%
发文量
151
审稿时长
2 months
期刊介绍: The Journal of Microbiology and Biotechnology (JMB) is a monthly international journal devoted to the advancement and dissemination of scientific knowledge pertaining to microbiology, biotechnology, and related academic disciplines. It covers various scientific and technological aspects of Molecular and Cellular Microbiology, Environmental Microbiology and Biotechnology, Food Biotechnology, and Biotechnology and Bioengineering (subcategories are listed below). Launched in March 1991, the JMB is published by the Korean Society for Microbiology and Biotechnology (KMB) and distributed worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信